MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
Real-time Estimate Cboe BZX  -  05/19 12:19:35 pm EDT
24.01 USD   +4.60%
05/18Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
05/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
05/05MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MIRUM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

01/11/2022 | 09:03am EDT

Item 2.02 Results of Operations and Financial Condition.

On January 11, 2022, Mirum Pharmaceuticals, Inc. (the "Company") issued a press release announcing, among other things, the Company's preliminary unaudited revenues for both the quarter and fiscal year ended December 31, 2021. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On January 11, 2022, in connection with its participation in the J.P. Morgan Healthcare Conference, the Company posted a corporate slide presentation in the "Investors" portion of its website at www.mirumpharma.com. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.

The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



Exhibit
  No.        Description

99.1           Press Release dated January 11, 2022

99.2           Investor Presentation dated January 2022

104          Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about MIRUM PHARMACEUTICALS, INC.
05/18Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
05/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
05/05MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/05TRANSCRIPT : Mirum Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Busines..
BU
05/05Mirum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/05Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Reports Q1 Revenue $12.9M, vs. Street Est o..
MT
05/02Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Confere..
BU
04/26SVB Leerink Adjusts Mirum Pharmaceuticals' Price Target to $49 from $46, Keeps Outperfo..
MT
04/08Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
More news
Analyst Recommendations on MIRUM PHARMACEUTICALS, INC.
More recommendations